Godrej Agrovet Q1 FY27: consol. PAT -14% YoY as margins compress, Crop Care still weak

Godrej Agrovet's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 9.2% YoY to ₹2,855.22 Cr, but consolidated PAT ("profit for the period") fell 13.8% YoY to ₹128.31 Cr (EPS ₹6.99 vs ₹8.35 a year ago), even as it rebounded 25.4% QoQ from a seasonally soft Q4 FY26 base of ₹102.28 Cr — that sequential jump reflects the return of the Q1 kharif-season pickup in an agri-linked business rather than a structural improvement, and should not be read as trend confirmation. Consolidated PBT (before exceptional items, including share of JV profit) fell 9.7% YoY to ₹181.13 Cr. Neither this quarter nor the year-ago quarter carried any exceptional items at the consolidated level, so the decline is entirely operating in nature.

The compression sits on operating margin: OPM eased to 8.41% from 10.32% a year ago (though up sequentially from Q4's seasonal low of 5.96%), while NPM fell to 4.49% from 5.69%. By segment, Crop Care Business (which houses Astec Lifesciences' agrochemical/CDMO operations) was the primary drag — revenue fell 13.3% YoY to ₹349.02 Cr and segment PBIT dropped 35.1% YoY to ₹75.55 Cr. Poultry & processed food PBIT collapsed 80.5% YoY to ₹0.87 Cr, and Dairy swung to a small segment loss of ₹(1.90) Cr from a ₹4.31 Cr profit despite 11.5% revenue growth. Offsetting this, Animal Nutrition (+12.6% revenue, +29.7% PBIT YoY) and the Vegetable Oil/Oil Palm business (+24.1% revenue, +14.7% PBIT YoY) delivered the momentum management had flagged — the latter coinciding with the inauguration of India's first integrated Oil Palm complex on July 20, 2026.

The stock went into the print at ₹566.95, up 1.1% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.

Against management's own guidance from the Q4 FY26 call — early double-digit consolidated revenue growth and mid-teens PBT growth for FY27, with Crop Care recovery expected only from Q2 and a continued Astec CDMO-led turnaround — Q1's 9.2% revenue growth trails the "early double-digit" mark, and PBT declined rather than growing mid-teens, a clear miss on pace even though management had itself signalled that Crop Care weakness would persist through Q1. No management press release accompanied this filing, so there is no company framing to cross-check against the numbers, and no reliable Street consensus estimates for this specific quarter turned up in public previews, so the print cannot be benchmarked against consensus. Standalone PAT, by contrast, rose 8.7% YoY to ₹183.60 Cr — the divergence from consolidated (>3%) owes mainly to a ₹49.7 Cr JV dividend booked at the standalone level (eliminated on consolidation) and to weaker subsidiary-level performance (Astec, Crop Care, Poultry) that only shows up post-consolidation. Separately, the company disclosed a CFO transition alongside results: S. Varadaraj will take early superannuation effective September 30, 2026, with Ravishankar A. (previously VP-Finance at HUL's Beauty & Wellbeing business) named incoming CFO from October 1, 2026, with no stated link to the quarter's performance. This sets up Q2 FY27 as the checkpoint for the guided Crop Care recovery and for whether full-year PBT growth can still close the gap to the guided mid-teens pace after a Q1 shortfall.